Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mediwound Ltd Ord Sh (NQ: MDWD )

15.56 +0.17 (+1.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 81,490
Open 15.53
Bid (Size) 15.50 (3)
Ask (Size) 16.20 (10)
Prev. Close 15.39
Today's Range 15.21 - 16.41
52wk Range 7.100 - 19.86
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire

Performance

YTD
+38.31%
+38.31%
1 Month
-5.70%
-5.70%
3 Month
+11.14%
+11.14%
6 Month
+38.31%
+38.31%
1 Year
+42.36%
+42.36%

More News

Read More
MediWound to Report First Quarter 2024 Financial Results
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
Preview: MediWound's Earnings
Via Benzinga
Recap: MediWound Q3 Earnings
Via Benzinga
Earnings Outlook For MediWound
Via Benzinga
MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
From MediWound Ltd.
Via GlobeNewswire
Earnings Scheduled For March 21, 2024
Via Benzinga
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in Two Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
From MediWound Ltd.
Via GlobeNewswire
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Via Benzinga
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
From MediWound Ltd.
Via GlobeNewswire
Earnings Scheduled For November 21, 2023
Via Benzinga
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Third Quarter 2023 Financial Results
From MediWound Ltd.
Via GlobeNewswire
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
From MediWound Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.